Back to Newsroom

Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement

CALGARY, April 27, 2015 /CNW/ – Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today announced that it  has entered into a Framework Agreement which sets forth the principal business terms for an equity investment and a license of RVX-208, for all indications, to Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Hepalink”) for China, Hong Kong, Taiwan and Macau (the “Territories”). The completion of the transaction remains subject to execution of a definitive stock purchase agreement and license agreement.

Click here to read more